Treatment of major depression in HIV-seropositive men

Journal of Clinical Psychiatry

Volumn 59, Issue 5, 1998, Pages 217-224

  Zisook, Sidney ^a,f   Peterkin, Joanna ^b,c   Goggin, Kathleen J ^e   Sledge, Paul ^d   Atkinson, J Hampton ^a   Grant, Igor ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c Department of Obstetrics Gynecology   (United States)

^d CALIFORNIA STATE UNIVERSITY   (United States)

^e UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT INDICATION;

EID: 0031776252     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v59n0502     Document Type: Article

References (52)

1. Elkin I, Shea T, Watkins JT, et al. National Institute of Mental Health Treatment of Depression Collaborative Research Program. Arch Gen Psychiatry 1989;46:971-982
2. Sotsky SM, Glass DR, Shea MT, et al. Patient predictors of response to psychotherapy and pharmacotherapy: findings in the NIMH treatment of depression collaborative research program. Am J Psychiatry 1991;148: 997-1008
3. Kocsis JH, Croughan JL, Katz MM, et al. Response to treatment with antidepressants of patients with severe or moderate nonpsychotic depression and of patients with psychotic depression. Am J Psychiatry 1990; 147:621-624
4. Popkin MK, Callies AL, Mackenzie TB. The outcome of antidepressant use in the medically ill. Arch Gen Psychiatry 1985;42:1160-1163
5. Preskorn SH, Burke M. Somatic therapy for major depressive disorder: selection of an antidepressant. J Clin Psychiatry 1992;53(9, suppl):5-18
6. Atkinson JH, Grant I. Natural history of neuropsychiatric manifestations of HIV disease. Psychiatr Clin North Am 1994;17(1):17-33
7. Brown GR, Rundell JR, McManis SE, et al. Prevalence of psychiatric disorders in early stages of HIV infection. Psychosom Med 1992;54:588-601
8. Grant I, Heaton RK, Atkinson H. Neurocognitive disorders in HIV-I infection, HNRC Group, HIV Neurobehavioral Center. Curr Top Microbiol Immunol 1995;202:11-32
9. Maj M, Janssen R, Starace F, et al. WHO neuropsychiatric AIDS study, cross sectional phase I. Arch Gen Psychiatry 1994;51:39-49
10. Ostrow DG. Psychiatric consequences of AIDS: an overview. Int J Neurosci 1987;32:647-659
11. Perry SW, Tross S. Psychiatric problems of AIDS inpatients at the New York Hospital: preliminary report. Public Health Rep 1984;99:200-205
12. Perkins DO, Stern RA, Golden RN, et al. Mood disorders in HIV infection: prevalence and risk factors in a nonepicenter of the AIDS epidemic. Am J Psychiatry 1994;151:233-236
13. Perry S, Jacobsberg LB, Fishman B, et al. Psychiatric diagnosis before serological testing for the human immunodeficiency virus. Am J Psychiatry 1990;147:89-93
14. Rosenberger P, Bornstein R, Nasrallah H. Psychopathology in human immunodeficiency virus infection: life-time and current assessment. Compr Psychiatry 1993;34:150-158
15. Williams JB, Rabkin JG, Remien RH, et al. Multidisciplinary baseline assessment of homosexual men with and without human immunodeficiency virus infection, II: standardized clinical assessment of current and lifetime psychopathology. Arch Gen Psychiatry 1991;48:124-130
16. Hintz S, Kuck J, Peterkin JJ, et al. Depression in the context of human immunodeficiency virus infection: implications for treatment. J Clin Psychiatry 1990;51:497-501
17. Atkinson JH, Grant I, Kennedy CJ. Prevalence of psychiatric disorders among men infected with human immunodeficiency virus. Arch Gen Psychiatry 1988;45:859-864
18. Levine SH, Bystritsky A, Baron D, et al. Group psychotherapy for HIV-seropositive patients with major depression. Am J Psychother 1991;45: 413-424
19. Targ EF, Karasic DH, Diefenbach PN, et al. Structured group therapy and fluoxetine to treat depression in HIV-positive persons. Psychosomatics 1994;35:132-137
20. Kelly JA, Murphy DA, Bahr GR, et al. Outcome of cognitive-behavioral and support group brief therapies for depressed, HIV-infected persons. Am J Psychiatry 1993;150:1679-1686
21. Fernandez F, Levy JK. Psychopharmacotherapy of psychiatric syndromes in asymptomatic and symptomatic HIV infection. Psychiatr Med 1991;9: 377-394
22. Evans DL, Perkins DO. The clinical psychiatry of AIDS. Curr Opin Psychiatry 1990;3:96-102
23. Rabkin JG, Harrison WM. Effect of imipramine on depression and immune status in a sample of men with HIV infection. Am J Psychiatry 1990; 147:495-497
24. Levine S, Anderson D, Bystritsky A, et al. A report of eight HIV-seropositive patients with major depression responding to fluoxetine. J Acquir Immune Def Syndr 1990;3:1074-1077
25. Perkins DO, Evans DL. Fluoxetine treatment of depression in patients with HIV infection. Am J Psychiatry 1991;148:807-808
26. Rabkin JG, Rabkin R, Harrison W, et al. Effect of imipramine on mood and enumerative measures of immune status in depressed patients with HIV illness. Am J Psychiatry 1994;151:516-523
27. Judd FK, Mijch AM, Cockram A. Fluoxetine treatment of depressed patients with HIV infection. Aust N Z J Psychiatry 1995;29(3):433-436
28. Singh N, Catalan J. The use of selective re-uptake inhibitors for the treatment of depression in patients with AIDS. In: Abstracts of the 9th International Conference on AIDS; June 6-11, 1993; Berlin, Germany. Abstract no. POB 11-1529
29. Rabkin JG, Wagner G, Rabkin R. Effects of sertraline on mood and immune status in patients with major depression and HIV illness: an open trial. J Clin Psychiatry 1994;55:433-439
30. Grassi B, Gambini O, Scarone S. Notes on the use of fluvoxamine as treatment of depression in HIV-1-infected subjects. Pharmacopsychiatry 1995;28(3):93-94
31. Schaerf FW, Miller RR, Lipsey JR, et al. ECT for major depression in four patients infected with human immunodeficiency virus. Am J Psychiatry 1989;146:782-784
32. Fernandez F, Levy JK, Samley HR, et al. Effects of methylphenidate in HIV-related depression: a comparative trial with desipramine. Int J Psychiatry Med 1995;25:53-67
33. Heaton RK, Grant I, Butters N, et al. The HNRC 500: neuropsychology of HIV infection at different disease stages. J Int Neuropsychol Soc 1995;1:231-251
34. Centers for Disease Control and Prevention. Classification system for human T-lymphotropic virus type III/lymphadenopathy-associated virus infections. MMWR Morb Mortal Wkly Rep 1986;35(No. 20, 19). Taken from: JAMA 1986;256:20-21, 24-25
35. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198
36. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
37. Spitzer RL, Williams JBW, Gibbon M, et al. Structured Clinical Interview for DSM-III-R. Washington, DC: American Psychiatric Press; 1990
38. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987
39. Beck AT. Depression: Clinical, Experimental and Theoretical Aspects. New York, NY: Hoeber; 1967
40. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
41. Keppel G. Design and Analyses: A Researcher's Handbook. Englewood Cliffs, NJ: Prentice Hall; 1991
42. Hollon SD, DeRubeis RJ. Placebo-psychotherapy combinations: inappropriate representations of psychotherapy in drug-psychotherapy comparative trials. Psychol Bull 1981;90:467-477
43. Rabkin JG, Williams JBW, Neugebauer R, et al. Maintenance of hope in HIV-spectrum homosexual men. Am J Psychiatry 1990;147:1322-1326
44. Ostrow D, Grant I, Atkinson JH. Assessment and management of the AIDS patient with neuropsychiatric disturbances. J Clin Psychiatry 1988;49(5, suppl):14-22
45. Perry S, Fishman B, Jacobsberg L, et al. Effectiveness of psychoeducational interventions in reducing emotional distress after human immunodeficiency virus antibody testing. Am J Psychiatry 1991;48:143-147
46. Markowitz JC, Rabkin JG, Perry SW. Treating depression in HIV-positive patients. AIDS 1994;8:403-412
47. Markowitz JC, Klerman GL, Clougherty KF, et al. Individual psychotherapies for depressed HIV-positive patients. Am J Psychiatry 1995;152: 1504-1509
48. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997;32(3):210-258
49. Shader RI, Greenblatt DJ. Protease inhibitors and drug interactions: an alert. J Clin Psychopharmacol 1996;16(5):343-344
50. Chiba M, Hensleigh M, Nishime JA, et al. Role of cytochrome P450 3A4 in human metabolism of MK-629, a potent human immunodeficiency virus protease inhibitor. Drug Metab Dispos 1996;24:307-314
51. Kumanr GN, Rodrigues AD, Buko AM, et al. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABTA-538) in human liver microsomes. J Pharmacol Exp Ther 1996;277:423-431
52. Harvey AT, Preskom SH. Cytochrome P450 enzymes: interpretation of the interactions with selective serotonin reuptake inhibitors, part II. J Clin Psychopharmacol 1996;16(5):345-355